



EVEREST ORGANICS LIMITED

CIN : L24230TG1993PLC015426

An ISO 9001:2015 & WHO GMP Certified Company

Corporate Office : # 1st Floor, Lakeview Plaza, Plot No.127 & 128, Amar Co-operative Society,
Opp. Madhapur Police Station Road, Near Durgam Cheruvu, Madhapur, Hyderabad - 500 033.
Tel : 040- 40040783

Dated: 13.02.2020

EOL/SEC/COMP/071/2019-20

To,
Bombay Stock Exchange,
P.J. Towers, Dalal Street,
Mumbai – 400001,
Maharashtra, India

Dear Sir/ Ma'am,

Sub: Submission of Disclosure under Regulation 29 (2) of SEBI (Substantial Acquisition of Shares and Takeover) Regulations, 2011 and Regulation 7 (2) read with Regulation 6(2) of SEBI (Prohibition of Insider Trading) Regulations, 2015:

With reference to the captioned subject, please find enclosed herewith the disclosure received from the acquirer M/s. BK Advance Research, LLP, Person Acting in Concert (PAC) wherein one of the Partner in LLP is a Promoter of the Company, in Form 29(2) under Regulation 29 of SEBI (Substantial Acquisition of Shares and Takeover) Regulations, 2011 and Form C under Regulation 7(2) read with Regulation 6(2) of SEBI (Prohibition of Insider Trading) Regulations, 2015.

Kindly take the above information on record.

Thanking You,

For Everest Organics Limited


Rekha Singh
Company Secretary

Encl: As above



Regd. Office & Factory : Aroor Village, Sadasivpet Mandal, Sangareddy Dist. Telangana - 502291.

Tel. : 08455 - 250186, 250113, 250115 Fax : 08455-250114

Email:everestaccounts1@yahoo.com Website : www.everestorganicsltd.com

DR. SRIHARI RAJU SRIKAKARLAPUDI

R/o. Plot No. 127 & 128, 4th Floor, Amar Co-operative Society, Opp. Madhapur Police Station Road, Near
Durgam Cheruvu, Madhapur, Hyderabad – 500033, Telangana
Mobile No. 9440061672; Email ID: drsksraju@gmail.com

Dated: 13.02.2020

To,

Bombay Stock Exchange,
P.J. Towers, Dalal Street,
Mumbai – 400001,
Maharashtra, India

The Compliance Officer,
Everest Organics Limited,
Aroor Village, Sadasivapet Mandal,
Sangareddy (Medak) District, Telangana

Sub: Disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeover) Regulations, 2011 and Regulation 7(2) read with Regulation 6(2) of SEBI (Prohibition of Insider Trading) Regulations, 2015:

Dear Sir/ Ma'am,

With reference to the captioned subject, please note that I, Dr. Srikakarlapudi Srihari Raju, designated partner of M/s. BK Advance Research, LLP, Person Acting in Concert as partner in LLP and being Promoter in Everest Organics Limited (hereinafter referred to as "the Company") is hereby submitting this disclosure for the intimation of acquisition of 2000 Equity Shares representing 0.025% of the equity share capital of the Company through open market. In this regard, I hereby submit the disclosure required under Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeover) Regulations, 2011 and Regulation 7(2) read with regulation 6(2) of SEBI (Prohibition of Insider Trading) Regulations, 2015.

Kindly take the above information on record.

Thanking You,
Yours' Faithfully


Dr. Sri Kakarlapudi Srihari Raju
Managing Director
DIN: 01593620



Disclosures under Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011

Name of the Target Company (TC)	EVEREST ORGANICS LIMITED		
Name(s) of the acquirer/transferor and Persons Acting in Concert (PAC) with the acquirer	BK ADVANCE RESEARCH, LLP		
Whether the acquirer belongs to Promoter/Promoter group	Person Acting in Concert (PAC)		
Name(s) of the Stock Exchange(s) where the shares of TC are Listed	BOMBAY STOCK EXCHANGE		
Details of the acquisition / disposal as follows	Number	% w.r.t. total share/voting capital wherever applicable	% w.r.t. total diluted share/voting capital of the TC (*)
Before the acquisition/disposal under consideration, holding of :			
a) Shares carrying voting rights	30768	0.385%	NIL
b) Voting rights (VR) otherwise than by equity shares			
c) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category)			
d) Total (a+b+c)			
Details of acquisition/sale			
a) Shares carrying voting rights acquired/ sale/ Transfer	2000	0.025%	NIL
b) VRs acquired otherwise than by equity shares			
c) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) acquired/sold			
d) Total (a+b+c)			

After the acquisition/sale, holding of:

a) Shares carrying voting rights	32768	0.41%	NIL
b) VRs otherwise than by equity shares			

c) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) after acquisition			
d) Total (a+b+c)	32768	0.41%	NIL
Mode of acquisition/sale (e.g. open market / off-market / public issue / rights issue / preferential allotment / inter-se transfer etc.)	Open Market		
Date of acquisition / sale of shares / VR or date of receipt of intimation of allotment of shares, whichever is applicable	12-02-2020		
Equity share capital / total voting capital of the TC before the said acquisition/sale	Rs. 80,000,000/- divided into 8000000 Equity Shares of Rs. 10/- each		
Equity share capital/ total voting capital of the TC after the said acquisition/sale	Rs. 80,000,000/- divided into 8000000 Equity Shares of Rs. 10/- each		
Total diluted share/voting capital of the TC after the said acquisition/sale	Rs. 80,000,000/- divided into 8000000 Equity Shares of Rs. 10/- each		

On Behalf of Acquirer


SriKakarlapudi Srihari Raju



Place: Hyderabad

Date: 13.02.2020

1. *Introduction*
 2. *Methodology*
 3. *Results*
 4. *Discussion*
 5. *Conclusion*
 6. *References*
 7. *Appendix*
 8. *Notes*
 9. *Tables*
 10. *Figures*
 11. *Supplementary Materials*
 12. *Correspondence*
 13. *Conflict of Interest*
 14. *Acknowledgments*
 15. *References*
 16. *Appendix*
 17. *Notes*
 18. *Tables*
 19. *Figures*
 20. *Supplementary Materials*
 21. *Correspondence*
 22. *Conflict of Interest*
 23. *Acknowledgments*
 24. *References*
 25. *Appendix*
 26. *Notes*
 27. *Tables*
 28. *Figures*
 29. *Supplementary Materials*
 30. *Correspondence*
 31. *Conflict of Interest*
 32. *Acknowledgments*
 33. *References*
 34. *Appendix*
 35. *Notes*
 36. *Tables*
 37. *Figures*
 38. *Supplementary Materials*
 39. *Correspondence*
 40. *Conflict of Interest*
 41. *Acknowledgments*
 42. *References*
 43. *Appendix*
 44. *Notes*
 45. *Tables*
 46. *Figures*
 47. *Supplementary Materials*
 48. *Correspondence*
 49. *Conflict of Interest*
 50. *Acknowledgments*
 51. *References*
 52. *Appendix*
 53. *Notes*
 54. *Tables*
 55. *Figures*
 56. *Supplementary Materials*
 57. *Correspondence*
 58. *Conflict of Interest*
 59. *Acknowledgments*
 60. *References*
 61. *Appendix*
 62. *Notes*
 63. *Tables*
 64. *Figures*
 65. *Supplementary Materials*
 66. *Correspondence*
 67. *Conflict of Interest*
 68. *Acknowledgments*
 69. *References*
 70. *Appendix*
 71. *Notes*
 72. *Tables*
 73. *Figures*
 74. *Supplementary Materials*
 75. *Correspondence*
 76. *Conflict of Interest*
 77. *Acknowledgments*
 78. *References*
 79. *Appendix*
 80. *Notes*
 81. *Tables*
 82. *Figures*
 83. *Supplementary Materials*
 84. *Correspondence*
 85. *Conflict of Interest*
 86. *Acknowledgments*
 87. *References*
 88. *Appendix*
 89. *Notes*
 90. *Tables*
 91. *Figures*
 92. *Supplementary Materials*
 93. *Correspondence*
 94. *Conflict of Interest*
 95. *Acknowledgments*
 96. *References*
 97. *Appendix*
 98. *Notes*
 99. *Tables*
 100. *Figures*
 101. *Supplementary Materials*
 102. *Correspondence*
 103. *Conflict of Interest*
 104. *Acknowledgments*
 105. *References*
 106. *Appendix*
 107. *Notes*
 108. *Tables*
 109. *Figures*
 110. *Supplementary Materials*
 111. *Correspondence*
 112. *Conflict of Interest*
 113. *Acknowledgments*
 114. *References*
 115. *Appendix*
 116. *Notes*
 117. *Tables*
 118. *Figures*
 119. *Supplementary Materials*
 120. *Correspondence*
 121. *Conflict of Interest*
 122. *Acknowledgments*
 123. *References*
 124. *Appendix*
 125. *Notes*
 126. *Tables*
 127. *Figures*
 128. *Supplementary Materials*
 129. *Correspondence*
 130. *Conflict of Interest*
 131. *Acknowledgments*
 132. *References*
 133. *Appendix*
 134. *Notes*
 135. *Tables*
 136. *Figures*
 137. *Supplementary Materials*
 138. *Correspondence*
 139. *Conflict of Interest*
 140. *Acknowledgments*
 141. *References*
 142. *Appendix*
 143. *Notes*
 144. *Tables*
 145. *Figures*
 146. *Supplementary Materials*
 147. *Correspondence*
 148. *Conflict of Interest*
 149. *Acknowledgments*
 150. *References*
 151. *Appendix*
 152. *Notes*
 153. *Tables*
 154. *Figures*
 155. *Supplementary Materials*
 156. *Correspondence*
 157. *Conflict of Interest*
 158. *Acknowledgments*
 159. *References*
 160. *Appendix*
 161. *Notes*
 162. *Tables*
 163. *Figures*
 164. *Supplementary Materials*
 165. *Correspondence*
 166. *Conflict of Interest*
 167. *Acknowledgments*
 168. *References*
 169. *Appendix*
 170. *Notes*
 171. *Tables*
 172. *Figures*
 173. *Supplementary Materials*
 174. *Correspondence*
 175. *Conflict of Interest*
 176. *Acknowledgments*
 177. *References*
 178. *Appendix*
 179. *Notes*
 180. *Tables*
 181. *Figures*
 182. *Supplementary Materials*
 183. *Correspondence*
 184. *Conflict of Interest*
 185. *Acknowledgments*
 186. *References*
 187. *Appendix*
 188. *Notes*
 189. *Tables*
 190. *Figures*
 191. *Supplementary Materials*
 192. *Correspondence*
 193. *Conflict of Interest*
 194. *Acknowledgments*
 195. *References*
 196. *Appendix*
 197. *Notes*
 198. *Tables*
 199. *Figures*
 200. *Supplementary Materials*
 201. *Correspondence*
 202. *Conflict of Interest*
 203. *Acknowledgments*
 204. *References*
 205. *Appendix*
 206. *Notes*
 207. *Tables*
 208. *Figures*
 209. *Supplementary Materials*
 210. *Correspondence*
 211. *Conflict of Interest*
 212. *Acknowledgments*
 213. *References*
 214. *Appendix*
 215. *Notes*
 216. *Tables*
 217. *Figures*
 218. *Supplementary Materials*
 219. *Correspondence*
 220. *Conflict of Interest*
 221. *Acknowledgments*
 222. *References*
 223. *Appendix*
 224. *Notes*
 225. *Tables*
 226. *Figures*
 227. *Supplementary Materials*
 228. *Correspondence*
 229. *Conflict of Interest*
 230. *Acknowledgments*
 231. *References*
 232. *Appendix*
 233. *Notes*
 234. *Tables*
 235. *Figures*
 236. *Supplementary Materials*
 237. *Correspondence*
 238. *Conflict of Interest*
 239. *Acknowledgments*
 240. *References*
 241. *Appendix*
 242. *Notes*
 243. *Tables*
 244. *Figures*
 245. *Supplementary Materials*
 246. *Correspondence*

1. *Journal of the American Medical Association*, 1997; 277: 100-104.

[illegible]

Handwritten signature: *Neeraj*

Stamp: EVEREST ORGANIZATION

Name: BK Advance Research, LLP	Others (PAC)	Equity Shares	30768 (0.385%)	Equity Shares	2000 Equity Shares (0.025%)	2,44,600/-	Buy	Equity Shares	32768 (0.41%)	12.02.2020
PAN: AAUFB4409]										
LLPIN: AAN-9113										
Registered Office										
Address: P.No. 127, S.Y.No. 47, Guttala Begumpet, Madhapur, Hyderabad - 500033										
Contact No.: 040-40040783										

*Note: "Securities" shall have the meaning as defined under regulation 2(1) (i) of SEBI (Prohibition of Insider Trading) Regulations, 2015.

12.02.2020 13.02.2020 Open Market

Details of Trading in derivatives of the Company by Promoter, Employee or Director of a listed company and other such persons as mentioned in Regulation 6(2).

Trading in derivatives (Specify type of contract, Futures or Options etc.)						Exchange on which the trade was executed
Types of Contract	Contract Specifications	Buy		Sell		
		Notional Value	Number of units (contracts*lot size)	Notional Value	Number of units (contracts*lot size)	
15	16	17	18	19	20	21
-	-	-	-	-	-	BSE Limited

Note: In case of Options, notional value shall be calculated based on Premium plus strike price of options.

Signature:



Name: Dr. Sri Kakarlapudi Srihari Raju



Date: 13.02.2020

Place: Hyderabad